XENON PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.61 USD | +0.63% |
|
-0.95% | -16.17% |
Presenter SpeechJason Gerberry (Analysts)Going with our next company presenter, and thanks for...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Companyâs product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Calendar
04/06/2024
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
38.61
USD
Average target price
58.22
USD
Spread / Average Target
+50.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.17% | 2.91B | |
| +9.83% | 115B | |
| +10.80% | 105B | |
| -10.84% | 22.71B | |
| -1.46% | 21.83B | |
| -11.04% | 18.18B | |
| -41.92% | 16.52B | |
| -15.11% | 16.01B | |
| +6.62% | 14.14B | |
| +17.53% | 10.71B |
- Stock Market
- Equities
- XENE Stock
- News Xenon Pharmaceuticals Inc.
- Transcript : Xenon Pharmaceuticals Inc. Presents at Bank of America Securities 2023 Healthcare Conference, May-10-2023 04
